Core Viewpoint - The company plans to establish its East China headquarters in Shanghai by signing a real estate lease agreement with Shanghai Yanlin Biotechnology Co., Ltd, which includes provisions for shared and free usage of certain areas [1][2][11] Summary by Sections 1. Overview of Related Transactions - The company intends to lease a property located at No. 5, Lane 276, Luding Road, Putuo District, Shanghai, from Shanghai Yanlin Biotechnology Co., Ltd for its East China headquarters [2][3] - The property consists of five floors, with the first floor partially provided for free as a product experience center and the second floor shared for customer reception [2][3] 2. Lease Details - The lease includes the 5th floor with an area of 825 square meters and the 3rd and 4th floors with a total area of 1,660 square meters, with a rental period from August 1, 2025, to July 31, 2028 [2][3] - The rental rate is set at RMB 6 per day per square meter, resulting in an annual rent of RMB 5,442,150 [2][3] - The company has chosen to pay the rent in a lump sum, receiving a 10% discount, leading to a total rent of RMB 12,239,910 [3][8] 3. Related Party Information - Shanghai Yanlin Biotechnology Co., Ltd is controlled by the same actual controller as the company, Chen Chunmei, thus constituting a related party transaction [3][4] - The company has not engaged in related transactions exceeding RMB 30 million in the past 12 months, and this transaction does not require shareholder approval [3][11] 4. Purpose and Impact of the Transaction - The lease aligns with the company's long-term strategic planning and business development needs, facilitating resource optimization and market expansion in East China [10][11] - The rental price is deemed fair and reasonable, ensuring no harm to shareholders, particularly minority shareholders [10][11] 5. Approval Process - The independent directors unanimously approved the lease agreement, confirming its alignment with the company's strategic goals and fair pricing [11][12] - The board meeting held on July 28, 2025, saw all attending directors vote in favor of the transaction, with related directors abstaining from the vote [11]

Group 1 - The core viewpoint of the news highlights the strong financial performance of BeiGene, with a significant revenue increase and a positive outlook from Morgan Stanley [1][2] - As of March 31, 2025, BeiGene reported total revenue of $1.117 billion, representing a year-on-year growth of 48.64% [1] - The company achieved a net profit attributable to shareholders of $1.27 million, marking a substantial year-on-year increase of 100.51% [1] Group 2 - BeiGene is a commercial-stage biotechnology company focused on developing and commercializing innovative molecular targeted and immunotherapy drugs for cancer treatment [2] - The company has a diverse product portfolio, including six internally developed clinical candidates, three of which are in late-stage clinical trials: zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor) [2] - Founded in Beijing in 2010, BeiGene was listed on the NASDAQ Global Select Market in February 2016 and has built a global team of over 1,300 employees as of July 2018 [2]

诺和诺德大跌21.6%，这家丹麦制药巨头下调全年销售额和利润预期。惠而浦大跌12.9%，这家家电企 业Q2业绩不及预期。生物技术公司Sarepta Therapeutics涨35.7%，公司获FDA批准恢复基因疗法Elevidys 用于杜氏肌营养不良症(DMD)治疗。大全新能源涨4.7%，光伏行业迎来情绪范式转变，小摩看好。 ...

来源：格隆汇APP 格隆汇7月29日丨生物技术公司Sarepta Therapeutics盘前暴涨超45%，公司获FDA批准恢复基因疗法 Elevidys用于杜氏肌营养不良症(DMD)治疗。 ...

Group 1 - The core viewpoint of the news highlights the financial performance and market position of BeiGene, with a significant increase in revenue and net profit [1][2]. - As of July 28, BeiGene's stock opened at $299.0 per share, with a market capitalization of $35.42 billion [1]. - Financial data shows that for the fiscal year ending March 31, 2025, BeiGene's total revenue is projected to be $1.117 billion, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders is expected to be $1.27 million, reflecting a growth of 100.51% [1]. Group 2 - On July 17, Morgan Stanley raised BeiGene's target price to $345, maintaining an "Overweight" rating [1]. - The company is set to disclose its fiscal year 2025 mid-term report on August 6, prior to the market opening [1]. - BeiGene is a commercial-stage biotechnology company focused on developing and commercializing innovative molecular targeted and immunotherapy drugs for cancer treatment, with a diverse product portfolio [2].

Group 1 - Tesla has reached a chip contract with Samsung, resulting in a nearly 1% increase in Tesla's stock price [1][3][14] - WeRide, a company under the brand 文远知行, has seen its stock rise over 11% after receiving the first autonomous driving license in Saudi Arabia for its Robotaxi service [1][3][10] - Graphene battery material company GRAPHJET TECHNOLOGY has experienced a significant increase of over 53% in its stock price [3][12] Group 2 - The major U.S. stock indices opened mixed, with the Nasdaq rising over 0.4% [3] - The Dow Jones Industrial Average is at 44,932.09, with a slight increase of 30.17 points or 0.07% [4] - The S&P 500 index is at 6,397.12, up by 8.48 points or 0.13% [4] Group 3 - In pre-market trading, 小马智行 has seen its stock rise over 7% after obtaining a new batch of smart connected vehicle demonstration operation licenses in Shanghai [3][10] - Alibaba's stock has increased nearly 2% in pre-market trading, attributed to its API call volume ranking fourth globally [13] - Brent crude oil has surpassed $69 per barrel, marking a 2.33% increase, the highest since July 18 [11]

美股生物技术公司Celcuity股价飙升210%，因公司实验性组合疗法在晚期试验中帮助延缓了乳癌扩散。 ...

智通财经7月28日电，生物技术公司Celcuity股价盘前飙升113%，因公司实验性组合疗法在晚期试验中 帮助延缓了乳癌扩散。 ...

Core Insights - Transgene and BioInvent are presenting updated data on BT-001, an oncolytic virus, at the ESMO Annual Meeting in October 2025 [1][2] - BT-001 is being evaluated in a Phase I/IIa study for its efficacy in treating advanced solid tumors [4] Group 1: Study Details - The study is a multicenter, open-label, dose-escalation trial assessing BT-001 as a monotherapy and in combination with pembrolizumab [4] - The Phase I part of the study has shown that BT-001 is well tolerated and has demonstrated initial efficacy, with clinical responses observed in 2 out of 6 refractory patients [3][4] - The treatment has converted "cold" tumors into "hot" tumors, inducing T-cell infiltration and PD(L)-1 expression in the tumor microenvironment [3] Group 2: Product Information - BT-001 is developed using Transgene's Invir.IO® platform and incorporates a Treg-depleting recombinant human anti-CTLA-4 antibody from BioInvent [3] - The collaboration between Transgene and BioInvent is a 50/50 partnership focused on the development of oncolytic viruses [3] Group 3: Company Background - Transgene specializes in designing and developing virus-based immunotherapies for cancer treatment, with a portfolio that includes multiple viral vector-based immunotherapeutics [6][8] - BioInvent focuses on discovering and developing novel immune-modulatory antibodies for cancer therapy, with several candidates in clinical programs [8]

Core Insights - The Jiangsu Future Industry Innovation and Entrepreneurship Competition showcased 56 projects focusing on key future industries such as brain-computer interfaces, new materials, hydrogen energy, and advanced storage, with 34 projects selected as "gold seeds" for investment [1][2][6] Group 1: Competition Overview - The competition is a significant platform for nurturing future industries in Jiangsu, organized by the Provincial Development and Reform Commission and supported by various investment and entrepreneurial associations [2] - The number of projects registered for this year's competition increased by nearly 40% compared to the first edition, indicating growing interest and innovation in the sector [2] - The final round involved rigorous processes including live presentations and real-time scoring, highlighting the high quality of projects that advanced to this stage [2] Group 2: Investment Opportunities - Winning projects will enter the Jiangsu Strategic Emerging Industry Fund's future industry angel fund project reserve, providing them with potential investment opportunities [3][6] - The Jiangsu Strategic Emerging Industry Fund has reached a scale of over 100 billion, establishing a solid foundation for the growth of emerging industries [2][6] - Successful cases from the fund include a 10 million yuan investment in a biotechnology company aimed at accelerating clinical research for cancer treatments [3] Group 3: Ecosystem and Support - The competition is part of a broader strategy to cultivate future industries through collaboration among government, enterprises, research institutions, finance, and society [5][6] - The Jiangsu government is implementing a three-year action plan (2024-2026) to accelerate the development of future industries, with the competition serving as a key initiative [5][6] - The selected projects will receive continuous support and tracking services from the Jiangsu High-tech Investment Group, enhancing their chances of success [6]